Anti-Natalizumab Antibodies
-
Bioanalytical Antibodies
-
Anti-idiotypic Antibodies
- Antibodies for Bioanalysis and Drug Monitoring
- Anti-Abatacept Antibodies
- Anti-Adalimumab Antibodies
- Anti-Alemtuzumab Antibodies
- Anti-Bevacizumab Antibodies
- Anti-Brentuximab Antibodies
- Anti-Cemiplimab Antibodies
- Anti-Certolizumab Antibodies
- Anti-Cetuximab Antibodies
- Anti-Daratumumab Antibodies
- Anti-Denosumab Antibodies
- Anti-Durvalumab Antibodies
- Anti-Eculizumab Antibodies
- Anti-Etanercept Antibodies
- Anti-Evolocumab Antibodies
- Anti-Golimumab Antibodies
- Anti-Infliximab Antibodies
- Anti-Ipilimumab Antibodies
- Anti-Natalizumab Antibodies
- Anti-Nivolumab Antibodies
- Anti-Omalizumab Antibodies
- Anti-Palivizumab Antibodies
- Anti-Panitumumab Antibodies
- Anti-Pembrolizumab Antibodies
- Anti-Pertuzumab Antibodies
- Anti-Ranibizumab Antibodies
- Anti-Rituximab Antibodies
- Anti-Secukinumab Antibodies
- Anti-Tocilizumab Antibodies
- Anti-Trastuzumab Antibodies
- Anti-Ustekinumab Antibodies
- Anti-Vedolizumab Antibodies
- Biosimilar Antibodies for Research Use
- Anti-IgG Fc Antibodies
- Recombinant Fully-Human Immunoglobulin Isotype Controls
- Anti-Biotherapeutic Antibody Quality Control and Characterization
- Characterization of Critical Reagents for Ligand Binding Assays
-
Anti-idiotypic Antibodies
s
s
s
Antibodies for bioanalysis and drug monitoring of natalizumab and biosimilars
Develop highly selective and sensitive PK and ADA assays for the monoclonal antibody drug natalizumab (Tysabri) using our range of ready-made anti-idiotypic antibodies.
- Inhibitory antibodies specific to natalizumab
- Fully human surrogate positive control or calibrator
- Sequence defined, well characterized reagents with secure supply
- Recombinant production, stringent quality control for batch to batch consistency
- Non-animal-derived antibodies, reducing the use of animals in science
Table 1. Antibodies Specific to Natalizumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
|---|---|---|---|---|---|---|
|
Natalizumab Inhibitory Type 1 |
HCA248 |
AbD21375 |
Fab-FH1 |
2.1 |
PK bridging ELISA |
|
|
HCA249 HCA249P |
AbD21375_hlgG1 |
Human IgG1 HRP |
2.1 |
PK bridging ELISA ADA control |
||
|
HCA250 |
AbD21384_hlgG1 |
Human IgG1 |
12.2 |
ADA control |
* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody DYKDDDDK- and His-6-tags
Anti-Natalizumab Inhibitory Antibodies (Type 1)
Type 1 anti-natalizumab antibodies inhibit the binding of the drug natalizumab to its target, human alpha4-beta1-integrin. They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
ELISA Protocols to Get You Started
PK Bridging ELISA
Fig. 1. Natalizumab PK bridging ELISA using antibodies HCA248 and HCA249P.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
ADA Bridging ELISA
Fig. 2. Natalizumab ADA bridging ELISA using antibody HCA249 or HCA250.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Related Products
Resources
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.